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Objectives: The study tested the feasibility of using a new portable mechanical compression device for the treatment of
claudication. The device applies intermittent non-pneumatic mechanical compression (IMC) to the calf. It was hypoth-
esized that it can offer a low-cost convinient option for patients and achieve good compliance and improved clinical
outcomes.
Methods: Thirty patients were enrolled in a randomized controlled single blind study. Fourteen patients were assigned to
active IMC. Sixteen control patients continued with medical treatment alone. Outcomes were recorded at baseline, after
one month, three months, and six months. The study examined changes in exercise tolerance using Initial Claudiacation
Distance (ICD) and Absolute Claudiaction Distance (ACD) as well as ankle-brachial index at rest (ABI-r) and
post-exercise (ABI-pe). All patients had stable claudication due to peripheral arterial disease (PAD) and were already
under best medical treatment (BMT). To be eligible for inclusion, patients had to be between the ages of 50 and 75 years,
had to have stable claudication with an absolute claudication distance >40 meters but <300 meters on a standardized
treadmill stress test (3.8 km/h at a 10% grade), have a resting ABI in the affected limb <0.8 with a drop of at least 0.15
following exercise, in whom surgical intervention was not expected for at least three months. Fourteen patients were
assigned to active IMC consisting of compressions 65 mm Hg in amplitude, applied for three 3-second compressions/
minute, two hours/day for three months. Sixteen control patients continued with BMT alone.
Results:Onemonth after treatment, ICD increased by 66% (P .001), ACD increased by 51.75% (P .005), and ABI-pe
increased by 42% (P  .01). Treatment effects were maintained or further improved after three months. ABI-r did not
increase at any time. Compliance exceeded 80%. Three months following cessation of therapy, claudication distances and
ABI-pe did not decrease significantly.
Conclusions: We concluded that the use of IMC of the calf for three months increased claudication distances and led to
objective improvements in ABI-pe. Intermittent mechanical compression may be a useful approach to patients with
continued claudication despite standard medical treatment. (J Vasc Surg 2010;51:857-62.)Intermittent claudication due to peripheral artery dis-
ease (PAD) affects 10% of the population above 70 years of
age,1,2 with an estimated 12 million sufferers in the USA
and 15 million in Europe.3 The progressive aging of the
population will lead to a significant increase in the world-
wide prevalence of claudication in coming decades, with a
corresponding economic impact.
The main goals of treatment for claudication are to
improve exercise tolerance (eg, as indexed by distance
walked until the onset of leg pain and the total distance a
patient is capable of walking) and to minimize potential
progression to critical limb ischemia (which can lead to
ulcers and necrosis, sometimes requiring amputation). The
standard therapeutic options for achieving these goals in-
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cise, pharmacological treatments, control of associated
medical diseases or risk factors, percutaneous transluminal
angioplasty, and revascularization surgery. These options,
however, are not applicable to all patients with claudication
and are not always effective, especially in the long term. For
example, the use of pharmacologic agents believed to be
potent enhancers of blood flow, demonstrated only modest
improvements in exercise tolerance.4 Regarding more in-
vasive approaches, the risks of perioperative morbidity and
mortality, the long term risks of graft failure and restenosis
following transluminal angioplasty suggest prudence when
it comes to mechanical intervention, be it surgical or endo-
vascular.5
Intermittent pneumatic compression (IPC) is a treat-
ment modality that has been used extensively for patients
with lymphoedema and in the prophylaxis of deep vein
thrombosis (DVT).6 Prior studies have also demonstrated
that IPC increases lower limb arterial flow and could there-
fore be useful in patients with PAD.7 Indeed, therapeutic
effects have been identified in studies showing a 3.2 
1.6-fold increase in resting popliteal artery blood flow in
patients with claudication in response to IPC applied to the
calf8 and isotope studies showing an increase in calf muslce
perfusion with IPC applied to the foot.9 Although promis-
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pursued extensively because of certain limitations. These
include the relatively high cost of IPC devices, patient
discomfort that may be experienced with the relatively high
compression pressures needed to increase arterial flow, and
the need for total patient immobility during treatment
sessions. As a result, even when prescribed, patient compli-
ance can be low, sub-optimal levels of compression are
frequently used to avoid pain, and patients frequently dis-
continue treatment. The cumbersome design and also the
cost of the device are therefore prohibitive factors in mak-
ing IPC a chronic home care option.
Recently a new, non-pneumatic electrical portable de-
vice for intermittent mechanical compression (IMC) has
been developed (the FM220, FlowMedic, Caesarea, Is-
rael), that is placed around the calf and generates intermit-
tent electrical mechanical pressure on the calf muscle (Fig
1). We hypothesized that use of IMC with the FM220
could be a new treatment option for intermitent claudia-
tion. Therefore, the objective of the present prospective
study was to evaluate the safety and effectiveness of IMC
used daily for three months to enhance exercise tolerance
and haemodynamic parameters in the lower limb in patients
with intermittent claudication due to PAD. Patients were
randomized to IMC in addition to best medical therapy
(BMT) versus continued BMT alone. The possibility of
comparing IPC treatment in a separate study group was
considered but rejected due to the aforementioned limita-
tions of IPC that would have significantly complicated the
study and due to the fact that IPC is not considered a
Fig 1. FM220 positioned on the calf. The cloth sleeves around
the calf generate intermittent electrical mechanical compression.standard treatment.METHODS
This was a prospective, randomized, controlled single
blind study that enrolled 30 patients with stable claudica-
tion due to PAD. This sample size was selected justified by
previous studies of IPC that enrolled patients with similar
characteristics and were able to demonstrate improvements
in total walk distance (ie, the absolute claudication distance
[ACD]), distance to the onset of claudication (ie, the initial
claudication distance [ICD]), and in the ankle-to-brachial
index (ABI).10-13 To be eligible for inclusion, patients had
to be between the ages of 50 and 75 years, had to have
stable claudication in only one leg as a result of a femoro-
popliteal affection with an absolute claudication distance
40 meters but 300 meters on a standardized treadmill
stress test (3.8 km/h, 10% grade), have a resting ABI in the
affected limb 0.8 with a drop of at least 0.15 following
exercise, in whom surgical intervention was not expected
for at least three months. Patients were excluded if they had
diabetes, were smokers, or had undergone prior surgical or
endovascular procedures. The presence of diabetes compli-
cates the evaluation of claudication distances because pe-
ripheral neuropathy can mask claudication pain and can
also lead to neuropathic pains. Changes in smoking habits
can also significantly impact on walk distance even in the
short term.14 However, changes in smoking habits are
notoriously difficult to control in clinical trials.15 Thus, our
aim was to control, as much as possible, factors which could
potentially confound our ability to assess the direct impact
of IMC on symptoms and arterial pressure in the leg. In
addition, it was required that patients had stable claudica-
tion, evidenced by demonstrated stability of absolute clau-
dication distance on two stress tests performed one week
apart; patients with over 20 meters difference in ACD
between the two tests were excluded. This study was ap-
proved by the local ethics committee and all patients pro-
vided informed consent prior to initiation of study related
tests and treatments.
Randomization and treatments. Patients who satis-
fied the inclusion and exclusion criteria were randomized in
a 1:1 ratio between a control group (n  16) who contin-
ued to receive best medical treatment only or to an IMC
treatment group (n  14), which received medical treat-
ment plus active treatment with the FM220 device. Pa-
tients were stratisfied between the groups to ensure com-
parability with respect to age and gender.
Patients in both study groups received best medical
treatment for at least one month prior to study enrollment
which, based on TASC II Guidelines16 and as is routine in
our clinic, included instructions to exercise for one hour per
day and antiplatelent therapy (aspirin or clopidogrel), treat-
ment with statins, antihypertension treatment (with an
ACE-inhibitor), and a hemorreological agent (pentoxifyl-
line). In addition, medications were kept constant during
the entire six-month study period in all the patients.
Patients randomized to the treatment group were
trained in the use of the FM220 IMC device and were
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the calf of the affected limb for three months.
In order to operate the device, the patient applies a
cloth sleeve that holds the FM220 device in place around
the calf. The device includes an electric motor that pulls on
the straps of the sleeve and exerts a fixed compression
pressure of approximately 65 mm Hg for three seconds,
three times per minute during the treatment. These treat-
ment parameters were selected according to prior studies in
which the impact of IMC on popliteal arteral flow was
optimized.7
The device also includes integrated software that
records the duration of use for each day and allows moni-
toring of the degree of compliance with the prescribed two
hour/day, seven days/week, three-month treatment pre-
scription. In order to assess compliance in an unbiased way,
the patients were not informed of the existence of this
software during the study.
Clinical evaluations and measurements. Following
enrollment, a detailed medical history was obtained and a
physical examination was performed. Also, the ankle-brachial
index was determined at rest (ABI-r) and post-exercise
(ABI-pe) following the standardized treadmill exercise test
(performed at 3.8 km/h with a gradient of 10%). The ABI
was calculated by dividing the larger of systolic pressures
measured in the dorsalis pedia artery and the posterior tibial
artery of the affected limb by the larger of the systolic
pressures measures in the brachial arteries of the two
arms.17 ABI-pe was determined, as described in earlier
literature, as the ABI measured one minute following com-
pletion of exercise.18
As indicated above, all patients were subjected to two
baseline stress tests on which ICD and ACD were mea-
sured. The ICD was defined as the distance walked before
the onset of pain in the calf of the affected limb. The ACD
was defined as the distance at which ischemic pain forced
the patient to stop exercising. The results of the second test
were used as baseline values to which treatment period tests
were compared.
Repeat measurements of ABI-r, ABI-pe, ICD and
ACD were obtained at study months one and three (ie,
during the period of treatment) and six months (ie, 3
months after ending treatment) to evaluate both the long
term effects of IMC treatment and the durability of the
effect following cessation of treatment. In all cases, mea-
surements of ABI-r, ABI-pe, ICD, and ACD were carried
out by an investigator who was blinded to study group
assignment. Both control and treatment group followed a
same protocol of visits and were informed at the same terms
about the study in order to minimize the potential differ-
ences in patient motivation.
Statistical analysis. Absolute and percent changes in
ABI-r, ABI-pe, ICD, and ACD were calculated for each
followup examination relative to their respective baseline
values. Results obtained in each group were expressed as
average ( standard deviation) or median (95% confidence
intervals [CI]) values. Within group comparisons were
made using aWilcoxon test for matched variables. Betweengroup comparisons were made using an OR-Mann Whit-
ney test for independent variables. Bonferroni corrections
were used in cases of multiple comparisons. All tests were
two-sided and a probability value (P-value) of 0.05 or less
was considered as statistically significant.
RESULTS
Baseline characteristics of the study participants, sum-
marized in Table I, show that the groups were well matched
for age, gender, and severity and duration of symptoms.
Furthermore, patients reported that they had not experi-
enced significant changes in their symptoms of claudication
over the last 12 months prior to the study.
At the end of the first month of follow-up, ICD in-
creased by 66% (P  .001, from a median of 150 [100;
300] meters to 250 [237.5; 310] meters; 95% CI [11;
139]) and ACD increased by 52% (P .005, from amedian
of 171 [102-300]meters to 260 [235-320]meters; 95%CI
[20; 131]) in the ICM treatment group (Figs 2 and 3).
Concomitantly, ABI-pe increased by 42% (P  .01, from
the baseline value of 0.22 to 0.31; 95% CI [0.09; 0.12]).
However, there was no significant change in ABI-r (3.17%
change, P  .18; Figs 4 and 5). In sharp contrast, there
were not significant changes in ICD, ACD, ABI-pe or
ABI-r in the control group (P  .1 for all parameters)
Table I. Baseline demographic and data
Treatment group Control group
P(n  14) (n  16)
Age (years) 58.9 59.1 N.S.
Male/Female (n) 12/2 14/2 N.S.
Symptom furation
(months) 35  18 31  15 .10
Hypertension (%) 50 50 N.S.
Hyperlipidemia (%) 64 62.5 N.S.
Baseline ABI-r (m) 0.63  0.09 0.59  0.02 N.S.
Baseline ABI-pe (m) 0.22  0.10 0.24  0.06 N.S.
Baseline ICD (m) 150 [100;300] 145 [90, 210] N.S.
Baseline ACD (m) 171 [102;300] 166 [150, 200] N.S.
ABI, Ankle-brachial index; ABI-r, Ankle-brachial index at rest; ABI-pe,
Ankle-brachial index post-exercise; ACD, absolute claudication distance;
ICD, Initial claudication distance.
Values are means  SD or median [1st quartile, 3rd quartile].
Fig 2. Initial claudication distance. P values for between group
comparisons: one month (P .001); three months (P .002); six
months (P  .002).during this same period.
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initially observed improvements in the ICD and ACD
trended further higher in the ICM treatment group, attain-
ing values of 85% (P .002; 95% CI [81; 237]) and 75.5%
(P  .002; 95% CI [91.7; 218]) compared with their
respective values (Figs 2 and 3). ABI-pe continued to
increase substantially, attaining a value that was 97% (P 
.003; 95% CI [0.09; 0.33]) above its baseline value (Figs
2-5). There were no changes in ABI-r throughout the study
period. Similarly, there were no significant changes in any
of the study parameters in the control group through the
Fig 3. Absolute claudication distance. P values for between group
comparisons: one month (P .005); three months (P .002); six
months (P  .002).
Fig 4. Ankle-to-brachial index at rest. No significant differences.
Fig 5. Post-exercise ankle-to-brachial index. P values for between
group comparisons: one month (P  .01); three months (P 
.002); six months (P  .003).end of the first three-month study period.In the post-treatment evaluation at six months (three
months after cessation of IMC treatment), the claudication
distances and the ABI-pe in the IMC treatment group
remained significantly better than in the control group and
did not differ significantly from their respective values
measured at three months. In the control group, these
values again did not show significant changes from baseline.
Patient compliance with IMC treatment was indexed
by the number of hours the device was used (as recorded
by the device’s internal software) expressed as a percent of
the expected number of hours had the patients used the
device two hours each day as originally instructed. Compli-
ance was 82% at the end of the first study month, and 78%
at the end of the third month of treatment. All patients in
both groups completed the study and all follow ups were
performed as scheduled.
DISCUSSION
Devices that apply positive pressure to the lower ex-
tremeties have been investigated for nearly a century as
prophylaxis for deep vein thrombosis,19 for treatment for
lymphedema,20 and for the treatment of peripheral arterial
disease.21 Gaskell and Parrot,9 as early as 1977, demon-
strated that mechanical compression improves blood flow
to the lower limbs of seated arteriopathic patients using
radioactive Xe133 to measure tissue perfusion. More re-
cently, Morgan et al22 used non-invasive duplex color flow
imaging and demonstrated increases in popliteal artery
volume flow induced by short-cycle mechanical compres-
sions applied to the leg. Several subsequent studies have
corroborated these early findings.8,11,23-26 These prior re-
sults have been obtained with pneumatic compression de-
vices that apply compressive forces over much of the lower
extremity and, in some cases, the foot.
In view of the clinical promise but practical limitations
inherent to pneumatic compression devices (the relatively
high cost of IPC devices, patient discomfort, and the need
for total patient immobility during treatment sessions), we
have investigated a new compact and portable device that
applies compressive forces generated by a miniature electric
motor to the calf muscle. This device is just designed for
ambulatory use, in a sitting position.
The major findings of the present study are that when
used in patients with claudication for two hours per day for
up to three months, intermitent mechanical compression
(IMC) provided by this device results in statistically and
clinically significant improvements in initial and absolute
claudication distances with increased post-exercise ABI.
The latter finding provides important objective evidence
indicating that IMC treatment improves ability to perfuse
the leg during exercise. The finding that post-exercise ABI
increases progressively over time and persistence of the
effect at least threemonths following cessation of treatment
further supports a fundamental beneficial effect on vascular
vasodilatory capacity. The fact that resting ABI did not
change in response to IMC also implies that the mechanism
of action of this form of therapy is related to improvement
in vasodilatory capacity and not to an effect on the under-
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that there were no adverse effects observed associated to the
use of the IMC device.
The observed insignificant changes in claudication dis-
tances and resting and post-exercise claudication distances
observed in the control group, which received best medical
treatment and unsupervised physical exercise are congruent
with prior published data.27 Specificially, it has been shown
that unsupervised exercise and pharmacotherapy in patients
with claudication does not provide significant symptomatic
benefits in a majority of patients. In any case, this control
group represents the patients we find in clinical pratice in
the best case scenario.
Another promising aspect of the present results relates
to the high rates of tolerability and patient compliance with
IMC treatment using the FM220 device. All pateints com-
pleted the study and, based on automated device tracking
tools, there was 80% compliance with a two hour/day
prescription. In contrast, rates of compliance are signfi-
cantly less with pneumatic devices. For example, Kakkos et
al26 and Ramaswami11 each reported a treatment regimen
completion rate of only 35% with pneumatic calf and foot
mechanical compression devices. This large difference in
compliance is expected to complicate potential studies aim-
ing at comparing IPC and IMC and will require a larger
study population to account for this aspect. Moreover, we
found that the improvement in these patients in our study
who were not as compliant was lesser (43% in ACD at one
month), although without statistical signification. Regard-
ing the cost, IMC device is$900 and patients must spend
$10 per month in disposable sleeves for one leg affected
while IPC systems reach $1500 and the investment in
disposable sleeves is $400.
Also, supervised exercise programs have been shown to
be effective in terms of significantly improving exercise
capacity.28 However, these programs are not available in
the majority of medical centers and the high cost and low
rates of compliancemakes them prohibitive formany health
systems and difficult to launch.
As discussed above, the improved post-exercise ABIs
observed following three months of IMC implies improved
vasodilatory mechanisms in the treated leg. Such improve-
ments could result from several different mechanisms. First,
there is mounting evidence that IMC improves perfusion
and tissue oxygenation during periods of active treat-
ment.22-24 This is believed to be due to differential pressure
drops in the arteries and veins during the rapid release of the
compression that increases arterio-venous pressure gradi-
ents, thus increasing blood flow. Such periodic increases in
blood flow during periods of IMC treatment could help
restore endothelial function which, in turn, could improve
the ability of the endothelium to release vasodilatory factors
(eg, nitric oxide and prostacyclin) in response to increased
shear stresses during exercise. Other potential mechanism
may relate to a modulation of the local veno-arterial reflex
(a local, sympathetic nervous system-mediated reflex that
modulates precapillary sphincter tone15) and the possibility
that increased flow may stimulate the formation of collat-erals which, in the long term, can improve perfusion of the
leg. However, these explanations are speculative, and the
present study was not designed to study the mechanisms of
action.
By design, the present study excluded patients with
diabetes mellitus and who were smokers. It will therefore
be interesting to confirm the present results in smokers and
in patients with diabetes, provided the relevant factors can
be contolled during the study period.15
CONCLUSION
The results of the present study show that two hours of
daily IMC on the calf provided by the FM220 device used
by patients with peripheral artery disease at home for three
months significantly increases claudication distance and is
associated with objective improvement in limb perfusion.
Clinical benefits are observed within a month of treatment
and objective evidence (in the form of improved post-
exercise ABIs) improve over time and persist for at leat
three months following cessation of treatment. IMC with
this device was well tolerated and there is a high degree of
compliance.
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